NICE, the organization that makes reimbursement recommendations for medicines used on the National Health Service in England and Wales, has provisionally turned down Santhera Pharmaceuticals’ Agamree (vamorolone) for funding, less than three months after the dissociative steroid was granted approval by the UK regulator, the MHRA.
Agamree, which was authorized by the MHRA to treat children aged four years and older with Duchenne muscular dystrophy (DMD) on 12 January, was positioned by Switzerland-based Santhera as a drug that offered far fewer side effects than
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?